drugset / Trial / NCT07305831

A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)

NCT07305831

Phase 1 Completed 62 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverTriple-blindTreatment

Summary

Researchers are looking for new treatments for HIV-1 (human immunodeficiency virus type 1) that are safe, well-tolerated, and can be taken less often. HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. Ulonivirine (MK-8507) is a study medicine designed to treat HIV-1 The goal of this study is to learn if ulonivirine does not increase the QT interval (a measure of heart rhythm on an electrocardiogram) above a certain amount. Researchers also want to learn what happens to the amount of ulonivirine in a healthy person's body over time.

Timeline

Start
2026-01-22
Primary completion
2026-04-09
Completion
2026-04-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 400 mg Oral
Subject Ulonivirine Small molecule Oral

Indications

No indication recorded.